Enzalutamide - Generic Drug Details

What are the generic drug sources for enzalutamide and what is the scope of patent protection?

Enzalutamide is the generic ingredient in two branded drugs marketed by Actavis Labs Fl Inc, Apotex, Zydus Pharms, Astellas, and Sandoz, and is included in six NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Enzalutamide has one hundred and ninety-two patent family members in thirty-six countries.

There are nine drug master file entries for enzalutamide. One supplier is listed for this compound. There are three tentative approvals for this compound.

Summary for enzalutamide

International Patents:	192
US Patents:	7
Tradenames:	2
Applicants:	5
NDAs:	6
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	388
Patent Applications:	6,934
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for enzalutamide
What excipients (inactive ingredients) are in enzalutamide?	enzalutamide excipients list
DailyMed Link:	enzalutamide at DailyMed

Recent Clinical Trials for enzalutamide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche	PHASE2
University of Arkansas	PHASE2
Novartis Pharmaceuticals	PHASE1

See all enzalutamide clinical trials

Generic filers with tentative approvals for ENZALUTAMIDE

Applicant	Application No.	Strength	Dosage Form
		80MG	TABLET;ORAL
		40MG	TABLET;ORAL
		80MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for enzalutamide

Drug Class	Androgen Receptor Inhibitor
Mechanism of Action	Androgen Receptor Antagonists Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers

Anatomical Therapeutic Chemical (ATC) Classes for enzalutamide

L02BB	Anti-androgens
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for ENZALUTAMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTANDI	Tablets	enzalutamide	120 mg and 160 mg	213674	1	2024-12-27
XTANDI	Tablets	enzalutamide	40 mg and 80 mg	213674	1	2021-03-31
XTANDI	Capsules	enzalutamide	40 mg	203415	3	2016-08-31

US Patents and Regulatory Information for enzalutamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	8,183,274
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	12,161,628
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	12,502,357
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No	9,126,941

Expired US Patents for enzalutamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	9,126,941
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012	9,126,941
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	9,126,941

EU/EMA Drug Approvals for enzalutamide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Xtandi	enzalutamide	EMEA/H/C/002639Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.	Authorised	no	no	no	2013-06-21	2013-04-26

International Patents for enzalutamide

Country	Patent Number	Title	Estimated Expiration
Australia	2013315619
Australia	2018200316
Brazil	112015005432
Canada	2884795
China	105358535

Supplementary Protection Certificates for enzalutamide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893196	2013C/074	Belgium		PRODUCT NAME: ENZALUTAMIDE (ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/13/846 20130625
1893196	SPC/GB13/079	United Kingdom		PRODUCT NAME: ENZLUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/846 20130625
1893196	CR 2013 00065	Denmark		PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
1893196	PA2013029,C1893196	Lithuania		PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130625
1893196	92338	Luxembourg		PRODUCT NAME: ENZALUTAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (XTANDI); FIRST REGISTRATION DATE: 20130625

Enzalutamide (Xtandi): Market Dynamics and Financial Trajectory, Patent/Exclusivity Timeline, and Generic/Biosimilar Risk

Last updated: June 19, 2026

Enzalutamide is a high-value oncology androgen-receptor inhibitor whose commercial trajectory has been shaped by (1) post-approval label expansion across metastatic and earlier disease settings, (2) sustained global demand from payer and site-of-therapy preferences, (3) bioshield and uptake dynamics for oral AR-targeted combinations, and (4) a tightening patent wall that governs generic entry timing and litigation risk. The revenue curve is driven less by patent “cliff” events and more by sequential loss of exclusivity by formulation, dosage strength, and use patents, plus country-by-country regulatory and patent linkage outcomes.

---

How has enzalutamide’s revenue trajectory evolved since launch?

Core trajectory

• Enzalutamide’s revenue growth followed FDA approvals expanding from metastatic castration-resistant prostate cancer (mCRPC) into earlier metastatic hormone-sensitive prostate cancer (mHSPC) settings through combination regimens.
• The financial inflection points align with new-label approvals, line-of-therapy penetration, and consolidation of AR pathway targeting as a standard of care in advanced prostate cancer.
• Ongoing revenue durability has been supported by oral administration convenience, long-term persistence in practice, and payer adoption in metastatic settings.

What drives peak and post-peak dynamics

• Indication creep: Each label expansion increases the addressable patient pool and shifts share toward AR-directed oral agents.
• Line-of-therapy effects: Treatment sequencing (post-docetaxel vs treatment-naïve metastatic pathways) determines duration of usage per patient.
• Combination adoption: Uptake rises when enzalutamide shows improved outcomes in combination or intensified strategies versus earlier standard-of-care regimens.
• Competition from other AR inhibitors and chemotherapy: Market share adjusts as alternative AR pathway agents (and access to docetaxel, abiraterone, cabazitaxel, and later-line therapies) affect prescribing behavior.

---

What market dynamics explain enzalutamide’s pricing, access, and payer adoption?

Payer and access mechanics

• Cost-effectiveness framing: Payers typically evaluate drug cost against survival endpoints and health economics in metastatic prostate cancer.
• Formulary management: Utilization is driven by tiering, prior authorization, step edits (often requiring documented castration resistance or treatment-naïve metastatic status), and restrictions on sequencing.
• Oral oncolytics shift site-of-care economics: Home administration reduces clinic infusion overhead relative to chemotherapy, which supports payer and provider acceptance if supported by outcomes and monitoring frameworks.
• Real-world persistence: Adherence and dose management influence realized sales versus modeled trial uptake.

Competitive pressure

• Enzalutamide faces pricing and access pressure from other androgen receptor axis drugs and from improved sequencing strategies that incorporate multiple agents.
• Share retention depends on how quickly prescribers switch to or add competitors in newly approved combinations and earlier settings.

---

Which enzalutamide indications drive sales and how does label expansion affect unit demand?

Indication clusters that typically sustain demand

• Metastatic castration-resistant prostate cancer (mCRPC) populations with prior therapy history
• Treatment-naïve mCRPC subsets (where applicable) and lines defined by prior androgen deprivation and chemotherapy exposure
• Metastatic hormone-sensitive prostate cancer (mHSPC) where enzalutamide can be used earlier in the disease course

Dose and regimen consistency

• Oral dosing and predictable administration supports stable utilization across cycles.
• Dose modifications due to AEs are a practical factor for net revenue per patient over time.

---

What is the patent estate for enzalutamide: how many patents protect the drug and its formulations?

Estate structure Enzalutamide’s protection is typically distributed across:

• Drug substance and key intermediates (core compound claims)
• Compositions/formulations (tablet formulation, excipient systems, coating or stability)
• Methods of treatment (specific indications, patient populations, or dosing schedules)
• Manufacturing processes (granulation, purification, polymorph control)

Why this matters commercially

• Even when core compound protection ends, method-of-use or formulation patents can slow generic entry for specific label claims or specific product presentations.
• Patent linkage strategies in the U.S. and country-specific exclusivity regimes can extend market exposure beyond the earliest compound expiration.

(The requested high-specificity patent-count and numbered list cannot be produced here without Orange Book listing-level details, which are not provided in the prompt.)

---

When does enzalutamide lose exclusivity in the U.S. and how do exclusivity periods interact with patent expiration?

How exclusivity usually works for small molecules

• Patent expiration ends the enforceable right on the covered claims.
• Regulatory exclusivities (where applicable) can extend marketing exclusivity beyond patent expiry, depending on statutory category and approval history.
• For generic entry in the U.S., patent-by-patent challenges and FDA “patent list” status determine whether approval is blocked or allowed with permitted carve-outs.

Practical outcome for launch risk

• Generic launch typically follows the earliest combination of: (1) unexpired blocking patents remaining on the Orange Book, and (2) successful Paragraph IV outcomes (if challenged), settlement terms, or final judgments.

(Country- and patent-specific dates are not included in the prompt, so a complete exclusivity timeline cannot be generated without creating errors.)

---

What Paragraph IV challenges and patent litigation risks affect enzalutamide’s generic launch?

Litigation-driven entry gating

• Paragraph IV certifications can lead to:
  • 30-month stay if a qualifying lawsuit is filed (U.S.)
  • Court rulings invalidating or non-infringing key patents
  • Settlement agreements that delay entry even if the challenger prevails procedurally

Commercial impact

• Even if the compound patent is near expiry, remaining formulation and method patents can delay “full” label launch and protect meaningful revenue.
• For payers, “AT/NA” substitution can still occur for unblocked strengths or indications while blocked indications remain restricted.

(No Orange Book Paragraph IV case list or docket details were provided, so case identifiers and dates cannot be enumerated.)

---

What is the Orange Book status of enzalutamide and what does it mean for generic substitution?

Orange Book linkage framework

• The Orange Book lists approved drug products and patents claiming:
  • active ingredient
  • formulation (composition)
  • method of use
  • manufacturing
• Generic substitution depends on which listed patents remain unchallenged or survive litigation, and on whether the generic product is “AB-rated” for the same strength and dosage form.

Substitution vs label carve-outs

• Generics can launch for non-protected indications if courts or stipulations limit enforcement.
• Even with a “launch,” restricted label coverage can reduce the addressable market and protect revenues.

(Orange Book listing details and patent-by-patent status were not supplied in the prompt.)

---

How does enzalutamide compare with other androgen receptor inhibitors in market share and competitive positioning?

Relative positioning drivers

• Clinical use case: Enzalutamide is positioned as a core AR inhibitor in advanced prostate cancer pathways.
• Oral convenience: Like competing AR agents, it benefits from oral administration but faces head-to-head preferences based on trial-proven sequencing and adverse event tolerability.
• Payer preference: Coverage decisions depend on formulary contracts and rebates, which can swing with competitor negotiations.

Commercial competitive dynamic

• When competing AR inhibitors secure earlier line adoption or superior outcomes in specific combinations, enzalutamide’s incremental demand can soften.
• When enzalutamide maintains consistent outcomes and tolerability, it retains share by inertia and ongoing protocol use.

---

Which delivery, dose, and formulation versions drive revenues and where do patents block generic manufacturing?

Where generics are commonly blocked

• Tablet formulation claims: If protected excipient systems or stability features are claimed, generic manufacturers face reformulation or infringement risk.
• Specific strength or dose form patents: Blocking can occur if patents cover the particular marketed strength or release profile.
• Manufacturing process claims: Process differences may avoid literal infringement but can trigger doctrine-based arguments in litigation.

Net effect

• Generics can sometimes launch “around” formulation patents, but courts or settlements may enforce delays for particular product configurations.

(No formulation patent numbers, strengths, or dosage forms are provided in the prompt.)

---

What biosimilar risk exists for enzalutamide and why is it usually low?

Biosimilar vs generic classification

• Enzalutamide is a small-molecule drug. Biosimilars apply to biologics, not small molecules.
• The relevant competition is generics and possibly authorized generics, not biosimilars.

Practical competitive substitutes

• The competitive threat is from small-molecule AR inhibitors and generic versions of enzalutamide post exclusivity.

---

What generic entry scenarios are most likely for enzalutamide?

Scenario types

1. Hard launch after patent expiration: Multiple patents expire with no settlement restriction; generics enter with broad label.
2. Staggered launches: Generics enter certain strengths or indications first due to partial blocking or claim carve-outs.
3. Settlement-mediated delay: Challengers settle to postpone entry in exchange for certainty on exclusivity.
4. Evergreening via method-of-use/formulation patents: Additional patents sustain practical barriers even after compound expiry.

Implications for revenue

• Staggered entry typically reduces revenue erosion versus a single “cliff.”
• Settlement delays often produce a more gradual decline and preserve gross margin for longer.

(Specific scenario probabilities require Orange Book and litigation outcomes that are not provided.)

---

Which companies are producing or challenging enzalutamide generics?

Key challengers

• This section requires a paragraph-IV challenger list, generic applicant names, and FDA filings tied to Orange Book patents.
• Without those filing lists, naming companies would risk inaccuracies.

(No manufacturer/challenger dataset was provided in the prompt.)

---

What regulatory pathways and FDA milestones shape enzalutamide’s market timing?

FDA pathway logic

• Branded originator: NDA/BLA history determines exclusivity and listing.
• Generics: ANDA pathway for small molecules requires patent certifications per 505(b)(2) or ANDA frameworks as applicable.
• Biosimilars: not applicable for enzalutamide due to small-molecule status.

Market timing drivers

• FDA acceptance, labeling, and patent certification timing can affect whether a generic launch date aligns with expiry or post-expiry litigation windows.

(No FDA milestone list is provided in the prompt.)

---

Financial exposure: how much of the enzalutamide market is at risk from generic competition and how fast does erosion occur?

Erosion pattern typical for high-value specialty oncology small molecules

• Generic erosion usually accelerates after first approved generic entry due to payer switching and increased price competition.
• Follow-on generics and authorized generics can further compress prices over time.

What determines speed

• Number of competing ANDAs approved
• Patent carve-outs limiting the label breadth
• Contractual payer arrangements (rebates and channel controls)
• Supply readiness and manufacturing capacity

(No current sales or unit projections were provided, so quantified “at risk” revenue figures cannot be computed without fabricating data.)

---

Timeline: how enzalutamide’s exclusivity, patent life, and generic entry windows typically unfold

A complete, date-accurate timeline requires:

• Orange Book patent list with expiration dates
• Any granted pediatric exclusivity or regulatory exclusivity periods
• Identified Paragraph IV filings and litigation milestones
• Settlement dates affecting entry

Those are not included in the prompt, so a correct timeline cannot be produced without risking errors.

---

Key Takeaways

• Enzalutamide’s revenue trajectory is primarily driven by label expansion into earlier metastatic disease settings and sustained AR-targeted standard-of-care adoption.
• Market dynamics are shaped by payer access controls, sequencing practices, oral convenience, and competitor AR inhibitor positioning.
• Generic risk is governed by Orange Book patent linkage and enforcement outcomes across compound, formulation, and method-of-use patents, typically producing staggered rather than instantaneous erosion.
• Biosimilar risk is effectively non-existent because enzalutamide is a small molecule; competition is generics and other small-molecule AR inhibitors.
• A precise exclusivity and litigation timeline cannot be stated from the provided input without Orange Book listing and case details.

---

FAQs

1) What is the main commercial threat to enzalutamide: patent cliff or label-specific carve-outs?
Label-specific carve-outs driven by formulation and method-of-use patent outcomes usually determine how quickly erosion starts and how broadly the generic can launch.

2) Do formulation patents matter for enzalutamide generics if compound patents expire first?
Yes. Formulation and method-of-use patents can restrict launch scope or delay approval for specific dosage presentations and protected indications.

3) How does dosing regimen tolerability affect real-world enzalutamide persistence?
Dose holds and reductions from adverse events can reduce realized dosage intensity and affect patient duration on therapy, impacting sales per patient.

4) Are there likely to be multiple generic launches at different times for enzalutamide?
Yes. Staggered entry can occur based on which patents remain listed, which are successfully challenged, and whether settlements delay specific applicants.

5) Does FDA approval timing alone determine enzalutamide generic launch dates?
No. Patent certification outcomes, litigation stays, and settlement terms often govern when generics can market, not only when the FDA approves.

---

References

1. FDA Orange Book. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Hatch-Waxman Act: Patent and Exclusivity Provisions (Orange Book patent listing and ANDA Paragraph IV framework). U.S. Food and Drug Administration.